{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2"},{"groupId":"OG001","value":"76.0"},{"groupId":"OG002","value":"84.9"}]}],"title":"ALT, Grade 0 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6"},{"groupId":"OG001","value":"19.0"},{"groupId":"OG002","value":"12.7"}]}],"title":"ALT, Grade 1 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"3.3"},{"groupId":"OG002","value":"1.6"}]}],"title":"ALT, Grade 2 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"0.8"}]}],"title":"ALT, Grade 3 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"ALT, Grade 4 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8"},{"groupId":"OG001","value":"24.0"},{"groupId":"OG002","value":"15.1"}]}],"title":"ALT, Grade 1-4 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"0.8"}]}],"title":"ALT, Grade 3-4 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4"},{"groupId":"OG001","value":"71.9"},{"groupId":"OG002","value":"81.7"}]}],"title":"AST, Grade 0 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5"},{"groupId":"OG001","value":"23.1"},{"groupId":"OG002","value":"15.1"}]}],"title":"AST, Grade 1 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"3.3"},{"groupId":"OG002","value":"2.4"}]}],"title":"AST, Grade 2 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"0.8"}]}],"title":"AST, Grade 3 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"AST, Grade 4 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6"},{"groupId":"OG001","value":"28.1"},{"groupId":"OG002","value":"18.3"}]}],"title":"AST, Grade 1-4 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"0.8"}]}],"title":"AST, Grade 3-4 (n=352, 121, 126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5"},{"groupId":"OG001","value":"93.4"},{"groupId":"OG002","value":"98.4"}]}],"title":"Total Bilirubin, Grade 0 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"4.1"},{"groupId":"OG002","value":"0.8"}]}],"title":"Total Bilirubin, Grade 1 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"0.8"}]}],"title":"Total Bilirubin, Grade 2 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.8"},{"groupId":"OG002","value":"0"}]}],"title":"Total Bilirubin, Grade 3 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Total Bilirubin, Grade 4 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5"},{"groupId":"OG001","value":"6.6"},{"groupId":"OG002","value":"1.6"}]}],"title":"Total Bilirubin, Grade 1-4 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.8"},{"groupId":"OG002","value":"0"}]}],"title":"Total Bilirubin, Grade 3-4 (n=353, 121, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7"},{"groupId":"OG001","value":"71.9"},{"groupId":"OG002","value":"71.1"}]}],"title":"Alkaline Phosphatase, Grade 0 (n=353, 121, 128)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8"},{"groupId":"OG001","value":"20.7"},{"groupId":"OG002","value":"24.2"}]}],"title":"Alkaline Phosphatase, Grade 1 (n=353, 121, 128)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8"},{"groupId":"OG001","value":"4.1"},{"groupId":"OG002","value":"3.9"}]}],"title":"Alkaline Phosphatase, Grade 2 (n=353, 121, 128)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"3.3"},{"groupId":"OG002","value":"0.8"}]}],"title":"Alkaline Phosphatase, Grade 3 (n=353, 121, 128)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Alkaline Phosphatase, Grade 4 (n=353, 121, 128)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3"},{"groupId":"OG001","value":"28.1"},{"groupId":"OG002","value":"28.9"}]}],"title":"Alkaline Phosphatase, Grade 1-4 (n=353, 121, 128)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"3.3"},{"groupId":"OG002","value":"0.8"}]}],"title":"Alkaline Phosphatase, Grade 3-4 (n=353, 121, 128)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"132"}],"units":"Participants"}],"description":"ALT=alanine aminotransferase; AST=aspartate aminotransferase. CTCAE v3.0 Grades 0 through 4 of severity for each AE based on this general guideline: Grade 0=Normal, Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE.","groups":[{"description":"Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288\\[288V\\]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217\\[210M\\]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"OG000","title":"Ipilimumab Plus gp100"},{"description":"Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with matching vaccine placebo. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"OG001","title":"Ipilimumab Monotherapy"},{"description":"Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288\\[288V\\]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217\\[210M\\]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"OG002","title":"gp100"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least 1 dose or any partial dose of study medication. N=Number of participants analyzed; n=number of participants with given laboratory evaluation.","reportingStatus":"POSTED","timeFrame":"On-study adverse events include all AEs reported between the first dose and 70 days after the last dose of study therapy (end of the study was defined as the time at which 481 deaths were observed [264 weeks]).","title":"Percentage of Participants With Worst On-Study Liver Abnormalities","type":"SECONDARY","unitOfMeasure":"percentage of participants"}